Location
Moultrie, GA
Start Date
7-5-2025 1:00 PM
End Date
7-5-2025 4:00 PM
Description
Introduction: Attention-Deficit/Hyperactivity Disorder (ADHD) is frequently treated with stimulant medications such as methylphenidate and amphetamines. However, concerns persist regarding the potential exacerbation or onset of tic disorders in children receiving stimulant therapy which often leads to hesitancy to begin or continue treatment. The U.S. Food and Drug Administration (FDA) has issued warnings about stimulant-induced tics, included in the packaging of dextroamphetamine (Adderall). There is conflicting evidence concerning the worsening of tics as a side effect to simulants, highlighting the need for careful clinical evaluation in patients with comorbid tic disorders prior to starting medication regimens. This study examines the relationship between stimulant use and tic disorders to inform clinical decision-making based on current published data.
Methods: A comprehensive literature review was conducted, including meta-analyses, randomized controlled trials, and observational studies evaluating the effects of stimulant medications on tic disorders. Data were extracted from the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), FDA medication labels, and published clinical guidelines. Studies assessing tic onset, severity, and management strategies were analyzed.
Results: Evidence suggests that while stimulant medications can precipitate or exacerbate tics in some individuals, the majority of children with ADHD and comorbid tic disorders tolerate stimulant therapy without significant worsening of symptoms. Some studies indicate that tic emergence may be dose-dependent, while others suggest a transient nature of stimulant-induced tics. Alternative pharmacological treatments, including alpha-2 adrenergic agonists (e.g., clonidine, guanfacine), have been associated with improved symptom management and reduced tic-related risks.
Discussion: The treatment of ADHD in children with comorbid tic disorders requires an individualized approach. While stimulants remain a viable option for many patients, clinicians must consider the potential for tic exacerbation and explore alternative treatment strategies when necessary. Close monitoring, patient-specific adjustments, and shared decision-making with caregivers are essential for optimizing therapeutic outcomes. Future research should further explore long-term outcomes and best practices for managing ADHD with comorbid tic disorders.
Embargo Period
6-3-2025
Included in
Stimulant use and comorbid tic disorders in the pediatric population: Clinical considerations and treatment implications
Moultrie, GA
Introduction: Attention-Deficit/Hyperactivity Disorder (ADHD) is frequently treated with stimulant medications such as methylphenidate and amphetamines. However, concerns persist regarding the potential exacerbation or onset of tic disorders in children receiving stimulant therapy which often leads to hesitancy to begin or continue treatment. The U.S. Food and Drug Administration (FDA) has issued warnings about stimulant-induced tics, included in the packaging of dextroamphetamine (Adderall). There is conflicting evidence concerning the worsening of tics as a side effect to simulants, highlighting the need for careful clinical evaluation in patients with comorbid tic disorders prior to starting medication regimens. This study examines the relationship between stimulant use and tic disorders to inform clinical decision-making based on current published data.
Methods: A comprehensive literature review was conducted, including meta-analyses, randomized controlled trials, and observational studies evaluating the effects of stimulant medications on tic disorders. Data were extracted from the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), FDA medication labels, and published clinical guidelines. Studies assessing tic onset, severity, and management strategies were analyzed.
Results: Evidence suggests that while stimulant medications can precipitate or exacerbate tics in some individuals, the majority of children with ADHD and comorbid tic disorders tolerate stimulant therapy without significant worsening of symptoms. Some studies indicate that tic emergence may be dose-dependent, while others suggest a transient nature of stimulant-induced tics. Alternative pharmacological treatments, including alpha-2 adrenergic agonists (e.g., clonidine, guanfacine), have been associated with improved symptom management and reduced tic-related risks.
Discussion: The treatment of ADHD in children with comorbid tic disorders requires an individualized approach. While stimulants remain a viable option for many patients, clinicians must consider the potential for tic exacerbation and explore alternative treatment strategies when necessary. Close monitoring, patient-specific adjustments, and shared decision-making with caregivers are essential for optimizing therapeutic outcomes. Future research should further explore long-term outcomes and best practices for managing ADHD with comorbid tic disorders.
Comments
Presented by Ericka Westbrook.